This #WorldBrainDay 2024, we want to highlight the significance of diversity and sample reliability in neurology research. A reported 50% of preclinical studies are irreplicable. This significant waste of time and resources is estimated to cost the United States $28 billion annually. One contributing factor is the use of #biospecimens that do not accurately represent the patient population. Additionally, many research studies categorize samples as "normal" when donors may have undetected or unknown pathologies. These practices introduce bias and inaccuracies into research, leading to unreliable results and hindering progress in the field. At BioIVT, we recognize the importance of sample diversity and quality in supporting neuro research and remain committed to providing the world's largest private repository of human #cerebrospinal fluid (CSF). This means you have access to a diverse pool of reliable biospecimens that are vital to enhancing the generalizability of study outcomes and ensuring that new treatments can benefit everyone. Samples are available across age, gender, and ethnicity, offering unmatched quality and reliability in biospecimen sourcing. Learn more about our available CSF samples for research: https://hubs.ly/Q02HqQbN0 #BrainDay2024 #DiversityInResearch #Neurology
About us
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our Research Services team works collaboratively with clients to provide in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
- Website
-
http://www.bioivt.com/
External link for BioIVT
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Hicksville, NY
- Type
- Privately Held
- Specialties
- Human and Animal Biologicals of the highest quality, Customized for every individual order, High level of customer service, Products delivered in a timely matter, ready for use, and Unconditional product guarantee
Locations
-
Primary
Post Office Box 770
Hicksville, NY 11802, US
Employees at BioIVT
Updates
-
The ICH M12 #DrugInteractions Guideline has been finalized and global regulatory agencies are already adopting it. Are you? The new Guideline replaces the corresponding guidance documents from the US FDA, EMA, and PMDA, among others. Join us tomorrow to hear DDI expert, Dr. Brian Ogilvie, discuss what’s new and how to plan your drug development strategies: https://hubs.ly/Q02HqM580 #DrugDevelopment #ADME #DMPK #Enzymes #DrugTransporters
-
The #scientificposter we presented at the #MicrophysiologicalSystems World Summit last month is now available. It demonstrates the utility of #HEPATOPAC for generating #siRNA mediated isogenic pairs for both #ADME and target screening applications. siRNA knockdown can be utilized to explore ADME-Tox related gene function in a well differentiated #hepatocyte model. Gene Knockdown in HEPATOPAC can be used to assess the effects of gene function on disease state modeling such as #MASLD and validate potential therapeutic modalities. #GalNAc conjugated siRNA can be utilized in the HEPATOPAC model and uptake and knockdown from these treatments is #ASGPR expression dependent. View the poster: https://hubs.ly/Q02GFHn00
Optimization of siRNA Delivery in a Long-Term Hepatic Micropatterned Co-Culture (HEPATOPAC) | BioIVT Educational Content
bioivt.com
-
#Diabetes increases the risk of heart failure by causing the death of heart muscle cells, potentially through a process called #ferroptosis. However, the exact role of ferroptosis in heart failure is not well understood. A recent study investigated ferroptosis by comparing heart tissue samples from people with diabetic heart failure to those from healthy individuals using de-identified heart tissue samples obtained from BioIVT. The study confirmed that cardiac ferroptosis plays a significant role in heart failure among people with diabetes. It also shed light on the molecular mechanisms involved, suggesting potential therapeutic targets to help manage heart failure complications in diabetic patients. Read the full study to learn more: https://hubs.ly/Q02Gy28T0 #HeartFailure #Research #HeartHealth
Regulation of cardiac ferroptosis in diabetic human heart failure: uncovering molecular pathways and key targets - Cell Death Discovery
nature.com
-
It’s critical that the correct species are selected for #preclinical #toxicology studies to accurately evaluate the safety of an NCE before it progresses to human clinical trials. Understanding the metabolic pathways of the NCE in different species #invitro increases the likelihood that the findings will be applicable to human safety. Learn more about in vitro cross-species comparison: https://hubs.ly/Q02Gy0190 #DrugMetabolism #ADME #DMPK
Metabolism: A Critical Factor in Species Selection for Nonclinical Toxicology Studies
bioivt.com
-
A lack of basic data accompanying #biospecimens prevents researchers from ensuring relevancy and quality during procurement as well as eventual reproducibility, calling the results of critical research into question. Read about the importance of and ways to utilize basic data to help ensure the accuracy of your research, including several case studies highlighting its impact: https://lnkd.in/eBMVSQSw #Pharma #Biotech #DrugDiscovery #Research
-
-
Next week, DDI expert Dr. Brian Ogilvie will be discussing the impacts of the newly finalized ICH M12 on #invitro #druginteractions study design and interpretation. The Guideline replaces corresponding guidance documents from the US FDA, EMA, and PMDA, among others. Make sure your studies meet these new regulatory expectations – learn more and register now: https://hubs.ly/Q02GxZFD0 #ADME #DMPK #DrugMetabolism #Enzymes #DrugTransporters
-
-
The condition of cells can have a big impact on your research. Understanding the relationship between temperature, time, and the stability of immune cell populations in #leukopaks is critical for maximizing the potential of human peripheral blood mononuclear cells (#PBMCs) in your #CellandGeneTherapy research. Read the whitepaper discussing our ASGCT 2024 poster for an in-depth look at cell viability following fresh leukapheresis under different simulated shipping conditions for insights that can help you define your approach to cell transport and preservation: https://lnkd.in/eVQKP_wD #CellTherapy #GeneTherapy #Biospecimens
Impact of Temperature Conditions on Cell Stability in Leukopaks
info.bioivt.com
-
New collaborative #scientificposter on #lysosomes presented this week at the GRC Drug Metabolism Conference: https://lnkd.in/eb9rrbDP Understanding the distribution and abundance of #drugtargets, metabolizing #enzymes, and #drugtransporters within liver subcellular compartments is crucial for #drugmetabolism and #toxicity studies. This study focused on identification and quantification using global quantitative #proteomics analysis.
Human liver lysosomes Biologics entering the cells by receptor-mediated uptake, e.g., antibody drug conjugates and related targeted modalities, are processed in the vesicles of endosomal-lysosomal pathway and can be catabolized in lysosomes. Specific metabolic reactions performed by lysosomal enzymes are essential for proper release and pharmacological activity of biologic’s payloads. In their catabolic capacity lysosomal enzymes act as a “microsomes for biologics”. Plurality of hydrolases contained in human liver lysosomes is scarcely characterized for metabolic activity, abundance, and regulation. Similarly, variability of these enzymes in individual donors and multiple organs has not been characterized. Dr. Prasad Research Group (https://pharmacy.wsu.edu/) provided proteomic characterization of BioIVT human liver lysosomes (HLL) from 15 donors (https://lnkd.in/gMgGSHTQ). Major findings of the work, presented this week at Gordon Research Conference (https://lnkd.in/gTdsdMBb) are 1) lysosomal markers (e.g., HEXA, HEXB, ACP2, and GUSB) are highly enriched and abundant in lysosomal preparation but not detected in human liver microsomes, 2) endoplasmic reticulum markers and mitochondrial markers are also detected in the lysosomal reparations, 3) multiple drug metabolizing enzymes and transporters are also enriched in HLL. These data enable proper design and interpretation of results of studies elucidating catabolism of biologics in lysosomes.
-
-
We understand your molecule is going through a unique journey, not only through the #drugdevelopment pipeline but also through the patient. BioIVT serves as a guide on this journey, helping you navigate the right path and understand the steps along the way. We can provide #biospecimens and #contractresearch services specific to your needs to help you understand your compound’s #ADME properties and risk of #DrugInteractions so you can avoid costly pitfalls such as late-stage failure and regulatory roadblocks. Our goal is to arm you with reliable, defendable data, and our in-house experts have been around long enough to understand regulatory expectations and to help you solve unique challenges. Let BioIVT be your resource—for test systems, services, consultancy, or field-specific scientific content—we have it all: https://hubs.ly/Q02FyQqV0